Schwab Charles Investment Management Inc. boosted its position in shares of BioScrip Inc (NASDAQ:BIOS) by 12.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 648,486 shares of the company’s stock after acquiring an additional 73,705 shares during the period. Schwab Charles Investment Management Inc. owned 0.51% of BioScrip worth $1,901,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently modified their holdings of BIOS. Mesirow Financial Investment Management Inc. increased its stake in BioScrip by 24.3% during the 2nd quarter. Mesirow Financial Investment Management Inc. now owns 114,541 shares of the company’s stock valued at $336,000 after purchasing an additional 22,382 shares in the last quarter. Sei Investments Co. increased its stake in BioScrip by 1,826.1% during the 2nd quarter. Sei Investments Co. now owns 124,024 shares of the company’s stock valued at $363,000 after purchasing an additional 117,585 shares in the last quarter. Rhumbline Advisers increased its stake in BioScrip by 16.9% during the 2nd quarter. Rhumbline Advisers now owns 126,878 shares of the company’s stock valued at $372,000 after purchasing an additional 18,372 shares in the last quarter. GSA Capital Partners LLP increased its stake in BioScrip by 40.7% during the 1st quarter. GSA Capital Partners LLP now owns 357,806 shares of the company’s stock valued at $880,000 after purchasing an additional 103,500 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of BioScrip by 53.8% in the first quarter. Dimensional Fund Advisors LP now owns 1,364,659 shares of the company’s stock worth $3,357,000 after acquiring an additional 477,611 shares during the period. Institutional investors and hedge funds own 84.87% of the company’s stock.
A number of analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of BioScrip from a “sell” rating to a “hold” rating in a research note on Tuesday. BidaskClub lowered shares of BioScrip from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 6th. Finally, Barrington Research reiterated a “buy” rating and issued a $4.00 price objective on shares of BioScrip in a research note on Friday, October 5th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $3.56.
NASDAQ:BIOS opened at $2.74 on Friday. The firm has a market capitalization of $396.94 million, a PE ratio of -6.20 and a beta of 0.07. BioScrip Inc has a 1-year low of $1.80 and a 1-year high of $3.26. The company has a current ratio of 1.91, a quick ratio of 1.60 and a debt-to-equity ratio of -4.21.
BioScrip (NASDAQ:BIOS) last released its quarterly earnings data on Tuesday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.04). The firm had revenue of $175.79 million for the quarter, compared to analysts’ expectations of $169.00 million. Research analysts predict that BioScrip Inc will post -0.32 EPS for the current fiscal year.
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
Featured Story: What is a Stop Order?
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.